Methods of treating ovarian cancer
The present invention provides methods of administering a PARP inhibitor to a cancer patient.
1. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, comprising
administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,
wherein the patient has undergone at least one cycle of platinum-based chemotherapy; and
wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.
2. The method of claim 1 , wherein the ovarian cancer, fallopian tube cancer, or primary peritoneal cancer is platinum sensitive.
3. The method of claim 1 , wherein the patient has undergone at least two cycles of platinum-based chemotherapy.
4. The method of claim 3 , wherein the patient has a complete response to the platinum-based chemotherapy.
5. The method of claim 3 , wherein the patient has a partial response to the platinum-based chemotherapy.
6. The method of claim 3 , wherein the administration of niraparib is commenced within 8 weeks of the end of the last cycle of platinum-based chemotherapy.
7. The method of claim 1 , comprising administering the niraparib in continuous 28-day cycles.
8. The method of claim 1 , wherein the niraparib is administered daily for a period of 6.9 months, and wherein administration is continued until disease progression occurs.
9. The method of claim 1 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate.
10. The method of claim 9 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 200 mg of niraparib free base.
11. The method of claim 9 , comprising administering daily to said patient an oral dose of niraparib tosylate monohydrate equivalent to 300 mg of niraparib free base.
12. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, the method comprising administering daily to said patient an oral dose of niraparib, wherein the patient is HRD negative and wherein the patient has undergone at least one cycle of platinum-based chemotherapy.
13. The method of claim 12 wherein the patient is BRCA1/2 wt .
14. The method of claim 12 wherein the patient is diagnosed as BRCA wt prior to administration of the oral dose of niraparib.
15. The method of claim 12 wherein the niraparib is administered to the patient for at least one 28 day cycle.
16. The method of claim 15 wherein the daily dose of niraparib is progressively reduced from an oral dose of niraparib equivalent to 300 mg to a dose of 200 mg of niraparib over the at least one 28 day cycle.
17. The method of claim 12 wherein the niraparib is administered to the patient prior to determining that the patient is HRD negative.
18. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, consisting of
administering daily to said patient an oral dose of niraparib equivalent to 200 mg or 300 mg of niraparib free base,
wherein the patient has undergone at least one cycle of platinum-based chemotherapy; and
wherein the patient carries no germline or somatic mutation in BRCA1 or BRCA2 genes and the cancer has no homologous recombination deficiency.
19. A method of treating a patient diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, the method consisting of administering daily to said patient an oral dose of niraparib, wherein the patient is HRD negative and wherein the patient has undergone at least one cycle of platinum-based chemotherapy.